Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET

The liver remains the primary site of iron storage, with liver iron concentration (LIC) being a strong surrogate of total body iron. MRI‐R2 can accurately measure LIC. The LICNET (Liver Iron Cutino Network) was established to diagnostics of liver iron overload by MRI‐R2 subjects with hemochromatosis in hematological disorders. The aims of the study were to look at variation in LIC measurements during time across different chelation regimens.

[1]  A. Maggio,et al.  The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major , 2017, British journal of haematology.

[2]  A. Taher,et al.  Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion‐dependent thalassaemia , 2017, European journal of haematology.

[3]  B. Giorgi,et al.  Real‐life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET , 2016, European journal of haematology.

[4]  Hsiu-Hao Chang,et al.  The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan , 2015, Annals of Hematology.

[5]  W. Wiktor-Jedrzejczak,et al.  Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias , 2015, Acta Haematologica.

[6]  D. Consonni,et al.  A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients , 2015, Annals of Hematology.

[7]  R. Sposto,et al.  Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload , 2014, American journal of hematology.

[8]  Tim G St Pierre,et al.  Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Noninvasive Measurement of Liver Iron Concentration , 2013, Magnetic resonance in medicine.

[9]  M. Cappellini,et al.  Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) , 2014 .

[10]  S. Rivella,et al.  Non-transfusion-dependent thalassemias , 2013, Haematologica.

[11]  Prapat Suriyaphol,et al.  Deferiprone (GPO‐L‐ONE®) monotherapy reduces iron overload in transfusion‐dependent thalassemias: 1‐year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO‐L‐ONE; A001) from Thailand , 2013, American journal of hematology.

[12]  A. Taher,et al.  Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy , 2012, Annals of Hematology.

[13]  E. Khoriaty,et al.  Iron in sickle‐cell disease: What have we learned over the years? , 2011, Pediatric blood & cancer.

[14]  A. Piga,et al.  Severe iron overload in Blackfan‐Diamond anemia: A case‐control study , 2009, American journal of hematology.

[15]  E. Vichinsky,et al.  Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload , 2009, British journal of haematology.

[16]  A. Taher,et al.  Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study , 2009, European journal of haematology.

[17]  G. D’Amico,et al.  Long‐term sequential deferiprone–deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial , 2009, British journal of haematology.

[18]  R. Galanello,et al.  A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. , 2006, Haematologica.

[19]  A. Silas,et al.  Liver biopsy 2005: when and how? , 2005, Cleveland Clinic journal of medicine.

[20]  M. Kami,et al.  Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.

[21]  A. Hoffbrand,et al.  Hepatic iron concentration combined with long‐term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major , 2000, British journal of haematology.

[22]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.